182 related articles for article (PubMed ID: 16162966)
1. Hypoxia inducible factor-1: a novel target for cancer therapy.
Belozerov VE; Van Meir EG
Anticancer Drugs; 2005 Oct; 16(9):901-9. PubMed ID: 16162966
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of hypoxia-inducible factor-1 signaling.
Belozerov VE; Van Meir EG
Curr Opin Investig Drugs; 2006 Dec; 7(12):1067-76. PubMed ID: 17209524
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
Lee K; Kim HM
Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Mooring SR; Jin H; Devi NS; Jabbar AA; Kaluz S; Liu Y; Van Meir EG; Wang B
J Med Chem; 2011 Dec; 54(24):8471-89. PubMed ID: 22032632
[TBL] [Abstract][Full Text] [Related]
5. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
6. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Wilczynski J; Duechler M; Czyz M
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):301-7. PubMed ID: 21625847
[TBL] [Abstract][Full Text] [Related]
7. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Wang JJ; Li J; Geng MY
Yao Xue Xue Bao; 2008 Jun; 43(6):565-9. PubMed ID: 18822956
[TBL] [Abstract][Full Text] [Related]
10. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez G; Giuliani A
J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
[TBL] [Abstract][Full Text] [Related]
12. Cancer therapy by targeting hypoxia-inducible factor-1.
Li Y; Ye D
Curr Cancer Drug Targets; 2010 Nov; 10(7):782-96. PubMed ID: 20578983
[TBL] [Abstract][Full Text] [Related]
13. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Yasuda Y; Arakawa T; Nawata Y; Shimada S; Oishi S; Fujii N; Nishimura S; Hattori A; Kakeya H
Bioorg Med Chem; 2015 Apr; 23(8):1776-87. PubMed ID: 25773014
[TBL] [Abstract][Full Text] [Related]
15. Identification of small molecule compounds that inhibit the HIF-1 signaling pathway.
Xia M; Bi K; Huang R; Cho MH; Sakamuru S; Miller SC; Li H; Sun Y; Printen J; Austin CP; Inglese J
Mol Cancer; 2009 Dec; 8():117. PubMed ID: 20003191
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of hypoxia-inducible factor 1 inhibitors against tumors].
Niu F; Li Y; Lai FF; Chen XG
Yao Xue Xue Bao; 2014 Jun; 49(6):832-6. PubMed ID: 25212028
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Otrock ZK; Hatoum HA; Awada AH; Ishak RS; Shamseddine AI
Crit Rev Oncol Hematol; 2009 May; 70(2):93-102. PubMed ID: 19186072
[TBL] [Abstract][Full Text] [Related]
18. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
[TBL] [Abstract][Full Text] [Related]
19. HIF-1alpha and cancer therapy.
Koh MY; Spivak-Kroizman TR; Powis G
Recent Results Cancer Res; 2010; 180():15-34. PubMed ID: 20033376
[TBL] [Abstract][Full Text] [Related]
20. Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia.
Nalini D; Selvaraj J; Kumar GS
J Cancer Res Clin Oncol; 2020 Jan; 146(1):1-18. PubMed ID: 31724069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
